Purpose. To report characteristics and outcomes of 8 patients who underwent intramedullary nailing for alendronate-associated femoral insufficiency fractures. Methods. Records of 7 women and one man aged 54 to 91 (mean, 72) years who underwent intramedullary nailing for spontaneous or low-energy, alendronateassociated femoral insufficiency fractures were retrospectively reviewed. Contralateral femurs were assessed for stress reactions. Results. All patients had at least 4 (range, 4-10) years of alendronate use. Five patients had experienced prodromal pain lasting one day to 5 months. Five patients had received concurrent glucocorticoid therapy. At the 6-month follow-up, 6 patients had bony union, one had hypertrophic non-union and underwent dynamisation and nail exchange and eventually achieved union at month 16, and one had fixation loss and underwent nail exchange and bone grafting and eventually achieved union at month 9. In Alendronate-associated femoral insufficiency fractures and femoral stress reactions 2011;19(1):89-92 3 patients, the contralateral femurs were painful, and cortical stress reactions were noted. They underwent prophylactic intramedullary nailing. Radiographs showed no evidence of new stress reactions or fractures. Conclusion. Contralateral involvement in patients with alendronate-associated femoral insufficiency fractures is not uncommon. Early prophylactic intramedullary nailing may provide effective pain relief and prevent progression to a fracture.
3 patients, the contralateral femurs were painful, and cortical stress reactions were noted. They underwent prophylactic intramedullary nailing. Radiographs showed no evidence of new stress reactions or fractures. Conclusion. Contralateral involvement in patients with alendronate-associated femoral insufficiency fractures is not uncommon. Early prophylactic intramedullary nailing may provide effective pain relief and prevent progression to a fracture.
INTRODUCTION
Alendronate has been widely used in the treatment of osteoporosis through inhibiting bone resorption, [1] [2] [3] but when such therapy is prolonged, there may be associated low-energy or spontaneous femoral fractures. [4] [5] [6] [7] [8] [9] [10] Patients with alendronate-associated femoral insufficiency fractures typically report a prodromal pain for one week to 2 years. 7, 8 Fractures usually occur during activities of daily living such as walking or turning; some patients experience sudden pain and feel a snapping sensation before they fall. 7 Fractures are typically of a simple transverse or oblique pattern at the subtrochanteric region or shaft, with a unicortical beak and diffused thickening of the proximal shaft cortex. [8] [9] [10] Long-term alendronate use leads to stress reactions in the lateral femoral cortex, which are the immediate precursors to fractures following minimal trauma. 8, 11 Moreover, femoral insufficiency fractures have been documented to arise at the exact location of cortical stress reactions. 8, 11 Cortical stress reactions may also exist in contralateral femurs and can progress to fractures. 7, 8, 11 As up to 76% of patients with alendronate-associated femoral insufficiency fractures have prodromal pain, 8 attention should be paid to those who also have cortical stress reactions. We report characteristics and outcomes of 8 patients who underwent intramedullary nailing for alendronate-associated femoral insufficiency fractures.
MATERIALS AND METHODS
Records of 7 women and one man aged 54 to 91 (mean, 72) years who underwent intramedullary nailing for spontaneous or low-energy, alendronate-associated femoral insufficiency fractures between August 2007 and July 2009 were reviewed. All fractures were of a simple transverse or oblique pattern at the subtrochanteric region or shaft, with a unicortical beak and diffused thickening of the proximal shaft cortex ( Fig. 1) .
Patients with a history of active malignancy, bone metastases, metabolic bone disorder, or renal impairment with a serum creatinine level of >150 µmol/l were excluded. 
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Contralateral femurs were assessed for stress reactions, which appeared as a small, localised thickening on the lateral aspect of the shaft or subtrochanteric femur, and corresponded to the unicortical beak seen in femoral insufficiency fractures. The decision to perform prophylactic intramedullary nailing was at the discretion of the surgeon.
RESULTS
All patients had at least 4 (range, 4-10) years of alendronate use. Five patients had experienced prodromal pain lasting one day to 5 months (Table) . Five patients had received concurrent glucocorticoid therapy. At the 6-month follow-up, 6 patients had bony union, one had hypertrophic non-union and underwent dynamisation and nail exchange and eventually achieved union at month 16, and one had fixation loss at 6 weeks and underwent nail exchange and bone grafting and eventually achieved union at month 9.
In patients 6, 7, and 8, the contralateral femur was painful, and cortical stress reactions were noted (Fig.  2) . They underwent prophylactic intramedullary nailing and were followed up for 6 to 18 months. All 3 patients were able to bear full weight without pain. Radiographs showed no evidence of new stress reactions or fractures. Alendronate treatment was continued in all, except for patient 8.
Patient 4 who had pain but no stress reaction had spontaneous pain relief several weeks later and remained pain-free. Patient 2 who had a stress reaction but no pain had not progressed to a fracture after 6 months. 
DISCUSSION
Alendronate-associated femoral insufficiency fractures usually arise from sites of cortical stress reactions. 7, 8 In a series of 17 patients with alendronateassociated femoral insufficiency fractures, 8 6 had radiological evidence of stress reactions affecting the contralateral femurs, whereas 3 of them subsequently sustained fractures. In a study of 7 patients with bilateral alendronate-associated fractures or stress reactions, 11 4 sustained bilateral femoral insufficiency fractures, whereas 3 had a unilateral fracture with contralateral stress reactions. 56% to 76% of patients with alendronate-associated femoral insufficiency fractures had a history of prodromal pain. 7, 8 The pain is typically sharp, well-localised to the mid or upper thigh, present only on weight bearing and ceasing when the patient is seated or lying down. The pain usually persists up to the day of the fracture and may serve as an indicator of impending fracture. If both pain and stress reactions present, a fracture is more likely to occur and a prophylactic intervention may become necessary. Patients with asymptomatic stress reaction should be treated conservatively.
Glucocorticoids have a suppressive effect on bone turnover. In our study, all 3 patients with stress reactions and pain in the contralateral femurs were also on long-term glucocorticoid therapy, compared to only 2 out of 5 patients who did not. Concurrent glucocorticoid and alendronate treatment may have an additive effect to the increase in the susceptibility to insufficiency fractures. 4 Whether such an increase can be attributed to a true additive effect of the 2 medications needs to be clarified.
Our study has limitations inherent in a retrospective case series. The number of patients was small; statistical comparison of associations was therefore not possible. There were no controls that had both stress reaction and pain and did not undergo prophylactic surgery. The follow-up period was short; longer follow-up is needed to confirm outcomes. Future investigations should aim to identify whether prophylactic surgery provides better outcomes for patients with stress reactions and pain, or whether protected weight-bearing alone is sufficient. In addition, whether discontinuing alendronate is effective in preventing further stress reactions or fractures needs to be clarified.
Alendronate is a popular drug for the treatment of osteoporosis. Greater awareness of the association between long-term alendronate therapy and femoral insufficiency fractures and its management is required. It is reasonable to screen the contralateral side of patients who have already sustained an alendronate-associated femoral insufficiency fracture, especially those who also have contralateral pain. Early prophylactic intramedullary nailing may provide effective pain relief and prevent progression to fractures.
